Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.02) earnings per share for the quarter, Zacks reports.
Mosaic ImmunoEngineering Stock Performance
Shares of CPMV stock remained flat at $0.69 on Wednesday. The business has a 50 day moving average price of $0.66 and a two-hundred day moving average price of $0.58. Mosaic ImmunoEngineering has a 1-year low of $0.25 and a 1-year high of $1.05. The stock has a market cap of $5.03 million, a price-to-earnings ratio of -6.95 and a beta of -0.68.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.
Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.
See Also
- Five stocks we like better than Mosaic ImmunoEngineering
- The Great AI Rotation: Cashing In on Data
- Mirum Pharma: A Rare Disease Growth Story to Watch
- The Great Cloud Divide: How AI Is Reshuffling the Software Deck
- Eagle Materials: A Dividend-Paying Brick & Mortar AI Play
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.
